Hyundai Motor Securities evaluated on Dec. 18 that Hanmi Pharmaceutical’s company worth continues to rise because the weight problems and metabolic dysfunction-associated steatohepatitis (MASH) therapy drug pipeline good points momentum. The goal inventory value was raised 37.5% from the prevailing 400,000 gained to 550,000 gained, with an funding opinion of “purchase” offered. The earlier buying and selling day’s closing value was 434,500 gained.
Yeo No-rae, a researcher at Hyundai Motor Securities, said, “The home Section 3 scientific information on Epeglenatide was introduced in October, proving wonderful weight reduction results and security on the 40-week level.” The analyst anticipated a home launch within the second half of subsequent yr, with market share acquisition anticipated primarily based on value competitiveness.
For Epinopegedutatide, which is present process Section 2b scientific trials concentrating on MASH sufferers, scientific trials might be accomplished on the finish of December, with main scientific information (topline) disclosure anticipated early subsequent yr.
Researcher Yeo stated, “Associate firm MSD (Merck) has excessive expectations,” including, “MSD’s growth standing presentation on the JP Morgan Healthcare Convention in January subsequent yr is noteworthy.”
For HM15275, which undergoes Section 2 scientific trials, outcomes are anticipated to be introduced in 2027. The corporate goals for home launch in 2030 and world launch in 2031. Researcher Yeo predicted, “Lately, retatrutide with the identical mechanism was confirmed to have a 28% weight reduction impact, which can create premium market demand for these wanting speedy weight discount.”
For HM17321, a Section 1 scientific trial started in November, with preliminary outcomes anticipated to be introduced within the first half of subsequent yr. Researcher Yeo evaluated, “As an weight problems therapy drug concentrating on CRFR2 receptors fairly than present GLP-1 collection, it’s a First-in-Class candidate substance displaying not solely fats discount but additionally muscle enhance results,” including, “It is going to be in a position to safe demand within the adjuvant market utilized in mixture with GLP-1 weight problems therapy medication.”
